Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials.

Objective

To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions.

Data sourcesand study selection

Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies.

Data extraction and synthesis

Two investigators abstracted data and appraised risks of bias. Intervention groups were categorized as "more intensive" (more potent pharmacologic intervention) or "less intensive" (less pote

SUBMITTER: Navarese EP 

PROVIDER: S-EPMC5933331 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature